Gilead and Arcellx Present Promising CAR-T Therapy Data at Hematology Meeting

At the annual meeting of the American Society of Hematology in Orlando, Florida, Gilead Sciences and its partner Arcellx revealed new data regarding their CAR-T therapy for multiple myeloma. The latest analysis from a pivotal-stage clinical trial indicated that among 117 patients enrolled, 96% exhibited a tumor response, with 74% achieving complete remission.

The companies noted no concerning safety issues in their report, highlighting the potential of their therapy to offer benefits over existing treatments for this challenging cancer type.